Jiangsu Qirui Pharmaceutical Technology Co., Ltd. is a joint venture established by Jiangsu Qirui Pharmaceutical Co., Ltd. and Hong Kong Maohui Company, dedicated to the research and development, production, and sales of products in the pharmaceutical field such as food, food for special medical purposes, medical devices, and drugs. It was registered in October 2018 in the Nantong Suxitong Science and Technology Industrial Park, with a registered capital of RMB 200 million and a total investment of over RMB 300 million. The company covers an area of 20,808 square meters (approximately 31 mu), with a total construction area of approximately 29,055.21 square meters (including the Phase II drug production workshop), including a gel (liquid) beverage workshop, a solid beverage workshop, a food and drug R&D and quality inspection center, a solid preparation workshop, an ampoule injection workshop, and corresponding ancillary works. In 2023-2024, a Phase II drug workshop will be newly built, with an estimated total construction area of 6,840 square meters (3 floors), consisting of a solid preparation workshop and a plastic ampoule injection workshop. The total investment of the company's Phase I food project is approximately RMB 160 million. It commenced construction in September 2020, was completed in January 2022, and obtained a food production license in June 2022, acquiring production capacity. The main production varieties in 2022 are: Hexaoshun (gel to assist swallowing medication), Shuhua series (thickeners), Yaoshun (nutritional thickener), peptide products, etc. The company is committed to providing eating convenience and nutritional support for people with dysphagia, people in specific disease states, the elderly, and others. The products developed, researched, and launched by the company all have invention patents or are products jointly developed with Japanese companies, with high exclusivity and technical content. Currently, one nutritional beverage has been launched and has applied for an invention patent, and another nutritional beverage is about to apply for an invention patent; the Phase II project diagnostic reagents have obtained invention patents and PCT patents, and have been granted patents in the United Kingdom, France, and Germany; a specific fully nutritional formula food is being jointly developed with Japan's NUTRI Company, the School of Food Science and Biotechnology of Zhejiang Gongshang University, and Sun Yat-sen University. The company's major shareholder, Shenzhen Jian'an Pharmaceutical Co., Ltd., was established in October 1985 and is a large pharmaceutical import and export enterprise with strong capital and distinctive characteristics. At present, Jian'an has 10 major regions, 31 districts, 238 offices, and more than 1,800 pharmaceutical information officers in major and medium-sized cities across the country, specializing in clinical academic promotion, adverse reaction monitoring, and other after-sales services, with annual sales of nearly RMB 3 billion.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows